25/02/2025 - Institutional news
On February 24, the Association Against Cancer in Barcelona awarded 49 research grants, three of which were for projects led by researchers from the Hospital del Mar Research Institute. In total, nearly 13 million euros have been allocated to boost cancer research in Barcelona. In the category of general project grants, Dr. Lluís Espinosa, coordinator of the Research Group on Molecular Mechanisms of Cancer and Stemness, received 292,200 euros to investigate how colon and rectal cancer cells resist treatments by acquiring characteristics similar to embryonic cells.
24/02/25 - General information
Hospital del Mar and its research institute are part of this project, which aims to develop nanophotonic sensors for the diagnosis and clinical management of bacterial infections at the point of care. On February 14, Hospital del Mar hosted the fourth follow-up meeting of the PHITBAC project. This initiative is driven by a consortium with public and private participation to develop rapid tests for the swift detection of bacteria, their antibiotic resistance, and antibiotic levels in the blood, all based on nanophotonics. Rapid diagnosis of microorganisms that cause severe infections remains an unresolved challenge in infectious disease management, and immediate bedside monitoring of antibiotic levels in severe infections is an unmet need.
21/02/2025 - General information
Dr. Joaquim Gea, Emeritus Head of the Pulmonology Department and researcher at the Hospital del Mar Research Institute, has been appointed as the coordinator of two special issues of the journals Cells and International Journal of Molecular Science. His role will involve selecting both the topics and the authors of the articles to be featured in these issues.
20/02/2025 - Press release
Researchers identify predictive markers of response to immunotherapy treatment in a study involving data from over 700 patients across six different cohorts, published in Nature Communications. The study has significant relevance, impacting the management of bladder cancer patients. Machine learning tools enabled the identification of key variables for the success of immunotherapy treatment. This innovative methodology has allowed researchers to pinpoint which tumor subtypes respond best to immunotherapy.
Més informació "Massive Data Analysis Advances the Understanding of How Immunotherapy Works"
13/02/2025 - Press release
Specifically, for every year of increase in the difference between chronological age (based on birthdate) and biological age (determined by lifestyle habits and exposure to external factors), the risk of developing cancer after any type of stroke increases by 6.6%. This is the first time a clear relationship has been established between biological age and cancer risk in these patients. Biological age can be modified by changing lifestyle habits, which could reduce the chances of developing cancer after recovering from a stroke.
11/02/25 - General information
At the Hospital del Mar Research Institute, every day we push science, medicine, and health forward. And we do it together. We are science, we are innovation, we are health. Professionals from all fields who research, care, create, and transform to advance knowledge and improve people's lives. We are the future. But we know there is still a long way to go. Science needs all perspectives, all voices, all talent. That's why today, we raise our voices. Because the world needs science, and science needs all of us. Today, we proudly celebrate the International Day of Women and Girls in Science, with commitment and the certainty that we are building a better future. Watch the video and share it!
06/02/2025 - Press release
The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their response to treatment. The device, which has already been successfully tested on breast cancer samples, could be key to developing new treatments and determining the most appropriate therapy for each patient in a personalized way. The work, published in Nature Communications, is the result of a collaboration between the Institute for Bioengineering of Catalonia and the Research Institute of the Hospital del Mar.
07/02/25 - General information
The Hospital del Mar Research Institute and the company Bionure have signed an agreement to establish a strategic collaboration between the two institutions. The objective is the development of new RNA-based therapies for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The research center will be responsible for conducting proof-of-concept studies for potential medications, both in patient cells and in animal models, which is a necessary step before starting clinical trials in humans. RNA therapies for these types of pathologies are a promising tool not only to slow disease progression but also to potentially repair neuronal damage in neurodegenerative diseases with a genetic component.
03/02/2025 - Institutional news
The latest call for independent research project grants from the Carlos III Health Institute has selected three projects led by researchers from the Hospital del Mar Research Institute. These projects involve three clinical trials in the fields of oncology, nephrology, and neurology. In total, they will receive close to 2.5 million euros.
23/01/2025 - Press release
According to a multicenter study published in the Journal of Hospital Infection, involving twelve hospitals across the country. Patients hospitalized due to healthcare-associated urinary tract infections caused by antibiotic-resistant bacteria require longer hospital stays-an average of three additional days compared to cases caused by bacteria that respond to treatment. The authors warn about the high number of cases caused by resistant bacteria, emphasizing the need to take stricter precautions in the use of antibiotics.
Servei de Comunicació:
Marta Calsina(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
